Opis działalności
Perrigo Company plc, a top five global over-the-counter ("OTC") consumer goods and pharmaceutical company, offers patients and customers high quality products at affordable prices. From its beginnings in 1887 as a packager of generic home remedies, Perrigo, headquartered in Ireland, has grown to become the world's largest manufacturer of OTC products and supplier of infant formulas for the store brand market. The Company is also a leading provider of generic extended topical prescription products and receives royalties from Multiple Sclerosis drug Tysabri®. Perrigo provides Quality Affordable Healthcare Products® across a wide variety of product categories and geographies primarily in North America, Europe, and Australia, as well as other markets, including Israel, China and Latin America.
Zarząd & Rada nadzorcza
| CEO |
| Patrick Lockwood-Taylor |
| Zarząd |
| Eduardo Bezerra, Grainne Quinn, Rob Willis, Ron Janish, Todd W. Kingma, Alison Ives, Roberto Khoury, Catherine "Triona" Schmelter |
| Rada nadzorcza |
| Orlando D. Ashford, Adriana Karaboutis, Bradley Alford, Donal O'Connor, Geoffrey M. Parker, Jeff Kindler, Katherine Doyle, Julia Brown, Patrick Lockwood-Taylor, Albert A. Manzone, Todd Penegor |
Dane firmy
| Nazwa: |
Perrigo Company plc |
| Adres: |
The Sharp Building, Hogan Place,IRL-Dublin 2, Ireland |
| Telefon: |
+1-353-1709-4000 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
www.perrigo.com/ |
| Przemysł: |
Służba zdrowia |
| Sektor: |
Przemysł Farmaceutyczny |
| Podsektor: |
Przemysł Farmaceutyczny |
| Koniec roku finansowego: |
31.12 |
| Free float: |
- |
| Data IPO: |
- |
